Journal of the American Chemical Society · 2026
Chiral Counteranion-Directed Asymmetric Intramolecular Rhodium-Catalyzed [(3+2+2)] Carbocyclization Reactions with Alkylidenecyclopropanes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Yu, Mao Zuqing, Evans P Andrew
Аннотация
Transition metal-catalyzed higher-order [m+n+o] carbocyclizations of alkylidenecyclopropanes (ACPs) provide atom-economical routes to complex polycyclic frameworks; however, achieving high enantioselectivity in these transformations remains extremely challenging. Herein, we report the first asymmetric intramolecular rhodium-catalyzed [(3+2+2)] carbocyclization of ACPs, enabled by asymmetric counteranion-directed catalysis (ACDC), to afford bridged tricyclic products with high diastereo- and enantioselectivity. Conventional ligand-controlled approaches failed to provide satisfactory reactivity or enantioinduction, whereas generating a chiral phosphate counteranion in situ from a silver phosphate (e.g., Ag-(S)-TRIP) via salt metathesis with a rhodium complex markedly enhanced enantioselectivity. Enantiomeric excesses of up to 93% were achieved using a matched combination of chiral phosphate and phosphoramidite ligands. The ACDC strategy also enables kinetic resolution of 1,5-diene-tethered ACPs in a new rhodium-catalyzed [(3+2+2)] carbocyclization, providing access to previously inaccessible tricyclic scaffolds with excellent stereocontrol. These results constitute rare examples of highly stereoselective rhodium-catalyzed higher-order carbocyclizations of ACPs and demonstrate that chiral counteranion-directed catalysis can enable asymmetric transition metal-catalyzed [m+n+o] cyclizations that remain inaccessible to conventional chiral-ligand control.